Answers are grounded in this paper and cite their sources.
Objective: To compare the efficacy of HFNO with NRM therapy in adult patients with acute hypoxemic respiratory failure. The primary endpoint was the proportion of patients requiring endotracheal intubation within 48 h of initiating respiratory support. Secondary endpoints included changes in SpO₂, respiratory rate, PaO₂/FiO₂ ratio, dyspnea severity, escalation of respiratory support, ICU length of stay, ICU mortality, device tolerance, and adverse events. Methods: A prospective, randomized, parallel-group controlled study was conducted involving 60 adult patients with acute hypoxemic respiratory failure. Patients were randomly allocated into two groups of 30 each. Group I received high-flow nasal oxygen, and Group II received oxygen through a non-rebreather mask. Peripheral oxygen saturation (SpO₂), respiratory rate, heart rate, arterial blood gas parameters, andPaO₂/FiO₂ ratio were assessed at predefined time points over 48 h. Results: Baseline demographic and clinical characteristics were comparable between the two groups mean SpO₂ increased from 86.9±3.1% at baseline to 96.1±1.5% at 60 min in Group I and from 87.2±3.0% to 93.8±2.1% in Group II. Respiratory rate decreased from 31.1±4.2 to 22.7±3.1 breaths/min in Group I and from 30.7±4.0 to 25.4±3.6 breaths/min in Group II. Treatment failure requiring endotracheal intubation occurred in 6 patients (20.0%) in Group I versus 11 patients (36.7%) in Group II (relative risk ≈0.55). Conclusion: HFNO was associated with greater improvement in oxygenation and respiratory rate and a lower proportion of treatment failure compared with NRM therapy. Larger adequately powered randomized controlled trials are required to establish the effectiveness of HFNO compared with NRM in acute hypoxemic respiratory failure.
No takes yet. Share an insight, caveat, or question.
GUPTA et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: